NEW YORK – Jacobio Pharma on Friday said the first non-small cell lung cancer patient with KRAS G12C and STK11 co-mutations has received JAB-21822 in a Phase IIa clinical trial underway in China.
In an earlier Phase I study, 56.3 percent out of 32 patients with KRAS G12C-mutated NSCLC responded to Jacobio's investigational KRAS inhibitor JAB-21822 and 90.6 percent achieved disease control.
Beijing-based Jacobio is evaluating JAB-21822 in several clinical trials as a monotherapy and in combination with other EGFR inhibitors and SHP2 inhibitors for pancreatic and colorectal cancer. After the US Food and Drug Administration cleared the firm's investigational new drug application for JAB-21822 last year, Jacobio opened several US sites for these trials.
For the trial that just began in KRAS G12C/STK11-mutant NSCLC patients in China, the firm is evaluating JAB-21822 as a monotherapy in the upfront treatment setting.